Results 201 to 210 of about 488,286 (382)

Reply

open access: yes
Arthritis &Rheumatology, EarlyView.
Spencer I. Danto, Elena Peeva
wiley   +1 more source

The efficacy of Telitacicept in Childhood‐onset Systemic Lupus Erythematosus: a prospective multi‐center cohort study with IPTW‐adjusted comparison to a historical control group treated with Belimumab

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The therapeutic effects of Telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with Belimumab combined with SoC. Methods We performed a prospective cohort study across 7 tertiary hospitals in China, enrolling patients ...
Chong Luo   +15 more
wiley   +1 more source

The effect of drugs in altering susceptibility to motion sickness in aerobatics and the slow rotation room [PDF]

open access: yes
Drugs altering susceptibility to motion sickness in aerobatics and slow rotation ...
Cawrse, A. C.   +3 more
core   +1 more source

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Juvenile idiopathic arthritis (JIA) is associated with impaired overall health‐related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient‐reported outcomes (PROs) in patients with JIA. Methods This was a post hoc analysis of a phase III, randomized, double‐blind, placebo‐controlled withdrawal trial (NCT02592434) in ...
Hermine I. Brunner   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy